HIF1A and neoplasm: ccRCC tumours that exhibit mono- or bi-allelic loss of HIF1A (collectively HIF1A loss) show worse overall survival (Fig. 7b) and progression-free survival (Supplementary Fig. 13c) than unaffected tumours, whereas there are no overall or progression-free survival differences between tumours with a copy number gain of HIF2A and unaffected tumours (Fig. 7c and Supplementary Fig 13d).